SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-132633
Filing Date
2020-12-07
Accepted
2020-12-07 07:30:24
Documents
13
Period of Report
2020-12-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2037507d2_8k.htm   iXBRL 8-K 24222
2 EXHIBIT 99.1 tm2037507d2_ex99-1.htm EX-99.1 12844
  Complete submission text file 0001104659-20-132633.txt   216844

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20201207.xsd EX-101.SCH 3183
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20201207_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20201207_pre.xml EX-101.PRE 22708
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2037507d2_8k_htm.xml XML 3745
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 201371338
SIC: 2834 Pharmaceutical Preparations